JP2002510494A5 - - Google Patents

Download PDF

Info

Publication number
JP2002510494A5
JP2002510494A5 JP2000542460A JP2000542460A JP2002510494A5 JP 2002510494 A5 JP2002510494 A5 JP 2002510494A5 JP 2000542460 A JP2000542460 A JP 2000542460A JP 2000542460 A JP2000542460 A JP 2000542460A JP 2002510494 A5 JP2002510494 A5 JP 2002510494A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
acid sequence
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000542460A
Other languages
English (en)
Other versions
JP2002510494A (ja
JP4227302B2 (ja
Filing date
Publication date
Priority claimed from US09/056,556 external-priority patent/US6350456B1/en
Priority claimed from US09/223,040 external-priority patent/US6544522B1/en
Application filed filed Critical
Priority claimed from PCT/US1999/007717 external-priority patent/WO1999051748A2/en
Publication of JP2002510494A publication Critical patent/JP2002510494A/ja
Publication of JP2002510494A5 publication Critical patent/JP2002510494A5/ja
Application granted granted Critical
Publication of JP4227302B2 publication Critical patent/JP4227302B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項１】
精製された免疫原性ポリペプチドであって、該ポリペプチドは、以下：
配列番号２のアミノ酸配列であって、該アミノ酸配列は、必要に応じて１つ以上の保存的アミノ酸置換を含有し、かつ、必要に応じてＮ末端におけるヒスチジン残基の伸展を伴わない、アミノ酸配列；または
配列番号２４のアミノ酸配列であって、該アミノ酸配列は、必要に応じて１つ以上の保存的アミノ酸置換を含有し、かつ、必要に応じてＮ末端におけるヒスチジン残基の伸展を伴わない、アミノ酸配列、
を含む、ポリペプチド。
【請求項２】
精製された免疫原性ポリペプチドであって、該ポリペプチドは、以下：
配列番号２のアミノ酸配列であって、該アミノ酸配列は、必要に応じて１つ以上の保存的アミノ酸置換を含有し、かつ、必要に応じてＮ末端におけるヒスチジン残基の伸展を伴わない、アミノ酸配列；または
配列番号２４のアミノ酸配列であって、該アミノ酸配列は、必要に応じて１つ以上の保存的アミノ酸置換を含有し、かつ、必要に応じてＮ末端におけるヒスチジン残基の伸展を伴わない、アミノ酸配列、
からなる、ポリペプチド。
【請求項３】
配列番号２および配列番号２４から選択されるアミノ酸配列を含む、精製された免疫原性ポリペプチド。
【請求項４】
配列番号２および配列番号２４から選択されるアミノ酸配列からなる、精製された免疫原性ポリペプチド。
【請求項５】
請求項１〜４のいずれか１項に記載のポリペプチドをコードする、ポリヌクレオチド。
【請求項６】
配列番号１および配列番号２３から選択されるヌクレオチド配列、あるいは配列番号１の遺伝子産物または配列番号２３の遺伝子産物と同一か、機能的に等価な遺伝子産物をコードする配列を含む、ポリヌクレオチド。
【請求項７】
配列番号１および配列番号２３から選択されるヌクレオチド配列、あるいは配列番号１の遺伝子産物または配列番号２３の遺伝子産物と同一か、機能的に等価な遺伝子産物をコードする配列からなる、ポリヌクレオチド。
【請求項８】
配列番号１および配列番号２３から選択されるヌクレオチド配列からなる、ポリヌクレオチド。
【請求項９】
請求項６〜８のいずれか１項に記載のポリヌクレオチドによってコードされる、ポリペプチド。
【請求項１０】
可溶性ポリペプチドである、請求項９に記載のポリペプチド。
【請求項１１】
組換えＤＮＡ法によって産生される、請求項９に記載のポリペプチド。
【請求項１２】
化学合成法によって生成される、請求項９に記載のポリペプチド。
【請求項１３】
抗体応答を誘導する、請求項９に記載のポリペプチド。
【請求項１４】
Ｔ細胞応答を誘導する、請求項９に記載のポリペプチド。
【請求項１５】
第２の異種ポリペプチドと融合される、請求項９に記載のポリペプチド。
【請求項１６】
請求項１〜４または請求項９〜１５のいずれか１項に記載のポリペプチドを含む、薬学的組成物。
【請求項１７】
請求項５〜８のいずれか１項に記載のポリヌクレオチドを含む、薬学的組成物。
【請求項１８】
請求項５〜８のいずれか１項に記載のポリヌクレオチドを含む、発現ベクター。
【請求項１９】
ウイルスベクターである、請求項１８に記載の発現ベクター。
【請求項２０】
請求項１〜４または請求項９〜１５のいずれか１項に記載のポリペプチド、およびアジュバントを含む、ワクチン組成物。
【請求項２１】
請求項５〜８のいずれか１項に記載のポリヌクレオチドを含む、ワクチン組成物。
JP2000542460A 1998-04-07 1999-04-07 Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ抗原の融合タンパク質およびその使用 Expired - Fee Related JP4227302B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/056,556 1998-04-07
US09/056,556 US6350456B1 (en) 1997-03-13 1998-04-07 Compositions and methods for the prevention and treatment of M. tuberculosis infection
US09/223,040 1998-12-30
US09/223,040 US6544522B1 (en) 1998-12-30 1998-12-30 Fusion proteins of mycobacterium tuberculosis antigens and their uses
PCT/US1999/007717 WO1999051748A2 (en) 1998-04-07 1999-04-07 Fusion proteins of mycobacterium tuberculosis antigens and their uses

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2006100968A Division JP4326008B2 (ja) 1998-04-07 2006-03-31 Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓ抗原の融合タンパク質およびその使用
JP2008149834A Division JP4516616B2 (ja) 1998-04-07 2008-06-06 Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ抗原の融合タンパク質およびその使用

Publications (3)

Publication Number Publication Date
JP2002510494A JP2002510494A (ja) 2002-04-09
JP2002510494A5 true JP2002510494A5 (ja) 2006-06-15
JP4227302B2 JP4227302B2 (ja) 2009-02-18

Family

ID=26735428

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000542460A Expired - Fee Related JP4227302B2 (ja) 1998-04-07 1999-04-07 Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ抗原の融合タンパク質およびその使用
JP2006100968A Expired - Fee Related JP4326008B2 (ja) 1998-04-07 2006-03-31 Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓ抗原の融合タンパク質およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006100968A Expired - Fee Related JP4326008B2 (ja) 1998-04-07 2006-03-31 Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓ抗原の融合タンパク質およびその使用

Country Status (17)

Country Link
US (2) US7186412B1 (ja)
EP (1) EP1068329A2 (ja)
JP (2) JP4227302B2 (ja)
KR (2) KR100692227B1 (ja)
CN (2) CN1629185B (ja)
AU (1) AU753995B2 (ja)
BR (1) BR9909472A (ja)
CA (1) CA2326598C (ja)
CZ (1) CZ302870B6 (ja)
HU (1) HU228354B1 (ja)
IL (1) IL138809A0 (ja)
NO (2) NO332500B1 (ja)
NZ (1) NZ507378A (ja)
PL (1) PL202844B1 (ja)
SA (1) SA99200488B1 (ja)
TR (1) TR200002938T2 (ja)
WO (1) WO1999051748A2 (ja)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
CN1629185B (zh) 1998-04-07 2011-11-02 科里克萨公司 结核杆菌抗原融合蛋白及其应用
AU6480999A (en) 1998-11-04 2000-05-22 Isis Innovation Limited Tuberculosis diagnostic test
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6448234B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20030027774A1 (en) * 1999-03-18 2003-02-06 Ronald C. Hendrickson Tuberculosis antigens and methods of use therefor
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US7009042B1 (en) 1999-10-07 2006-03-07 Corixa Corporation Methods of using a Mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of the heterologous proteins
DK1517913T3 (da) * 1999-10-07 2007-06-18 Corixa Corp En Mycobacterium tuberculosis-kodende sekvens til ekspression af heterologe proteiner
AU779978B2 (en) * 1999-10-07 2005-02-24 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US6316205B1 (en) 2000-01-28 2001-11-13 Genelabs Diagnostics Pte Ltd. Assay devices and methods of analyte detection
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
GB0006692D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Epitopes
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20030175700A1 (en) 2000-04-21 2003-09-18 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
SI1542732T1 (sl) * 2000-06-20 2010-01-29 Corixa Corp Csc The United Sta Fuzijski proteini Mycobacterium tuberculosis
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US6841159B2 (en) 2002-01-30 2005-01-11 The United States Of America As Represented By The Secretary Of The Navy Rapid lateral flow assay for determining exposure to Mycobacterium tuberculosis and other mycobacteria
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2005061534A2 (en) * 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
US8475735B2 (en) 2004-11-01 2013-07-02 Uma Mahesh Babu Disposable immunodiagnostic test system
CA2586620C (en) 2004-11-16 2014-06-03 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
CN100368437C (zh) * 2005-01-28 2008-02-13 中国农业科学院哈尔滨兽医研究所 一种诊断牛结核病的重组抗原蛋白及其制备方法
DK1877426T3 (da) 2005-04-29 2012-05-14 Glaxosmithkline Biolog Sa Fremgangsmåde til forebyggelse eller behandling af M Tuberculosis-infektion.
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN100999550B (zh) * 2006-01-10 2010-10-06 中国人民解放军第三○九医院 结核分枝杆菌融合蛋白及其应用
CN100415771C (zh) * 2006-06-06 2008-09-03 中国人民解放军第二军医大学 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途
CN101298471B (zh) * 2006-06-06 2011-01-19 中国人民解放军第二军医大学 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途
CN101311190B (zh) * 2006-06-06 2011-08-03 中国人民解放军第二军医大学 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途
CN101311189B (zh) * 2006-06-06 2010-09-08 中国人民解放军第二军医大学 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途
EP2040745B1 (en) * 2006-06-28 2012-12-05 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2086582B1 (en) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccine comprising an oil in water emulsion adjuvant
BRPI0717219B8 (pt) 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
SI2137210T1 (sl) 2007-03-02 2017-01-31 Glaxosmithkline Biologicals S.A. Nov postopek in sestavki
MX351247B (es) 2007-04-04 2017-10-05 Infectious Disease Res Institute Star Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
WO2009049097A1 (en) * 2007-10-13 2009-04-16 Cornell University Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis
KR101378240B1 (ko) 2008-02-22 2014-03-28 포항공과대학교 산학협력단 결핵 예방용 조성물
AU2010222930B2 (en) 2008-07-16 2013-07-25 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
MX2011000982A (es) 2008-07-25 2011-03-02 Glaxosmithkline Biolog Sa La proteina de tuberculosis rv2386c, composiciones y usos de la misma.
BRPI0916705A2 (pt) 2008-07-25 2015-11-10 Glaxo Group Ltd polipeptídeo isolado, polinucleotídeo isolado, composição farmacêutica, composição imunogênica, método para tratamento ou prevenção de tuberculose, e, usos de um polipeptídeo, e de um polinucleotídeo.
LT2315773T (lt) * 2008-07-25 2016-11-10 Glaxosmithkline Biologicals S.A. Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
CN102770457A (zh) 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
CA2754862C (en) * 2009-03-10 2019-04-02 Baylor Research Institute Anti-cd40 antibodies and uses thereof
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
HUE031184T2 (en) 2010-01-27 2017-06-28 Glaxosmithkline Biologicals Sa Modified tuberculosis antigens
DK2544693T3 (en) 2010-03-09 2017-12-04 Biomedical Res Models Inc Hitherto UNKNOWN ACCESS TO VACCINATION THROUGH MILKHINDER AGAINST HERPES SIMPLEX VIRUS TYPE-2
US9352030B2 (en) * 2010-12-14 2016-05-31 Glaxosmithkline Biologicals, S.A. Mycobacterium antigenic composition
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
CN102154324B (zh) * 2010-12-29 2012-11-28 兰州大学 结核分枝杆菌融合蛋白Mtb10.4-Hsp16.3的构建、表达和纯化方法及其应用
CA2831294A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
CN102305855A (zh) * 2011-05-19 2012-01-04 中山大学 体外检测结核分枝杆菌感染的试剂和方法
EP2771469A4 (en) * 2011-10-24 2015-04-08 Univ Central Florida Res Found ANTIGENS ESAT-6 AND MTB72F VACCINES AGAINST MYCOBACTERIUM TUBERCULOSIS EXPRESSED BY PLASTS AND FUSIONED AT SUBUNIT B OF CHOLERA TOXIN
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
MX347154B (es) 2012-02-24 2017-02-21 Centro De Investigación Científica Y De Educación Superior De Ensenada Baja California (Cicese) Prueba de diagnóstico para enfermedades infecciosas en ganado bovino.
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
CN102757971B (zh) * 2012-08-07 2013-09-11 中国人民解放军第三O九医院 一种结核分枝杆菌重组蛋白质及其制备方法
WO2014063704A2 (en) * 2012-10-23 2014-05-01 Statens Serum Institut M. tuberculosis vaccines
ES2847930T3 (es) 2013-01-07 2021-08-04 Mucosal Vaccine Tech Llc Vacunas terapéuticas para el tratamiento de las infecciones por el virus del herpes simple de tipo 2
JP2016516075A (ja) * 2013-03-15 2016-06-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 結核の予防または治療用の合成免疫原
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP6741580B2 (ja) 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
EP3992210A1 (en) 2014-01-13 2022-05-04 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CA3014458A1 (en) * 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
WO2017200852A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Formulation containing tlr agonist and methods of use
MX2018013640A (es) 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
MX2021010105A (es) 2016-06-01 2022-06-16 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento.
CA3067224A1 (en) 2017-06-15 2018-12-20 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
CN109825497A (zh) * 2019-01-25 2019-05-31 石河子大学 一种新型结核杆菌融合菌株的制备方法及其应用
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU5741590A (en) 1989-05-04 1990-11-29 Southern Research Institute Improved encapsulation process and products therefrom
JPH07500961A (ja) 1990-10-01 1995-02-02 ユニバーシティ オブ コネチカット 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定
WO1992020316A2 (en) 1991-05-14 1992-11-26 University Of Connecticut Targeted delivery of genes encoding immunogenic proteins
ES2149774T3 (es) 1991-06-05 2000-11-16 Univ Connecticut Aportacion dirigida de genes que codifican proteinas secretoras.
PT528306E (pt) * 1991-08-15 2000-05-31 Hoffmann La Roche Iniciadores e sondas de micobacterias
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young GENTHERAPY USING TARGETED VIRAL VECTORS.
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
DK79793D0 (da) * 1993-07-02 1993-07-02 Statens Seruminstitut Diagnostic test
DK79893D0 (da) * 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ES2378051T3 (es) * 1995-09-01 2012-04-04 Corixa Corporation Compuestos y métodos para el diagnóstico de la tubercolosis.
TR200806258T2 (tr) * 1995-09-01 2008-10-21 Corixa Corporation Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
US6627198B2 (en) * 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6544522B1 (en) * 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
CN1629185B (zh) 1998-04-07 2011-11-02 科里克萨公司 结核杆菌抗原融合蛋白及其应用

Similar Documents

Publication Publication Date Title
JP2002510494A5 (ja)
CA2555013A1 (en) Carcinoembryonic antigen fusions and uses thereof
JP2002537791A5 (ja)
JP2006187292A5 (ja)
JP2006149406A5 (ja)
CA2395499A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
JP2008545393A5 (ja)
RU98118319A (ru) Гены рецептора трансферрина moraxella
JP2002500043A5 (ja)
JP2003516731A5 (ja)
JP2003510050A5 (ja)
JP2004502460A5 (ja)
CA2385325A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
CA2196555A1 (en) Vr-2332 viral nucleotide sequence and methods of use
JP2008543314A5 (ja)
RU2004134341A (ru) Экспрессирующая система
WO2001046420A3 (en) Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
JP2009540801A5 (ja)
CA2389206A1 (en) Activation of hcv-specific t cells
CA2337100A1 (en) Polypeptides of lymphodendritic cell adhesion molecules (ldcams) and polynucleotides encoding the same
JP2002542827A5 (ja)
CA2248667A1 (en) Hla-a2.1 binding peptides and their uses
JP2002533125A5 (ja)
JP2004502446A5 (ja)
WO2001066778A3 (en) Production of foreign polypeptides in plants as viral coat protein fusions